Literature DB >> 1164816

Studies on the disposition of antipyrine, aminopyrine, and phenacetin using plasma, saliva, and urine.

E S Vesell, G T Passananti, P A Glenwright, B H Dvorchik.   

Abstract

In normal male subjects, the half-lives of antipyrine, aminopyrine, or phenacetin were not significantly different from the half-lives of each drug in saliva. Apparent volumes of distribution (aVd) in plasma and saliva differed by the extent to which each drug has been reported to bind to plasma proteins. Thus, the aVd of antipyrine in plasma and saliva was similar; there were significant differences in aVd for aminopyrine; even greater differences were observed for penacetin. The expression (see article) equals the fraction of the drug bound to plasma proteins. Rates of appearance in the urine of metabolites of antipyrine and aminopyrine were measured. General equations were used to show the relationship between half-life for elimination of the parent drug from the body and rate of excretion of metabolites. There were significant correlations between the half-life for elimination of antipyrine from the body and the half-life for production of 4-OH antipyrine (r equal 0.90), as well as between the plasma half-life of aminopyrine and the half-life of 4-aminoantipyrine (r equal 0.95). No significant correlation was observed in the same individual between the plasma half-lives of antipyrine and phenacetin (r equal 0.05, p greater than 0.05), of aminopyrine and phenacetin (r equal 0.11, p greater than 0.05), or of antipyrine and aminopyrine (r equal 0.50, p greater than 0.05).

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1164816     DOI: 10.1002/cpt1975183259

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  39 in total

Review 1.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

2.  Antipyrine - new light on an old drug.

Authors:  H Derendorf; G Drehsen; P Rohdewald
Journal:  Pharm Res       Date:  1984-09       Impact factor: 4.200

Review 3.  Assessment of liver metabolic function. Clinical implications.

Authors:  J Brockmöller; I Roots
Journal:  Clin Pharmacokinet       Date:  1994-09       Impact factor: 6.447

4.  Salivary antipyrine half-life: a useful measure of hepatic drug metabolism.

Authors:  P M Brooks; M A Bell; H Burns
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335

Review 5.  Therapeutic drug monitoring in saliva.

Authors:  M Danhof; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

6.  Effect of vitamin C supplement on antipyrine disposition in man.

Authors:  J B Houston
Journal:  Br J Clin Pharmacol       Date:  1977-04       Impact factor: 4.335

7.  D-glucaric acid excretion in critical care patients--comparison with 6 beta-hydroxycortisol excretion and serum gamma-glutamyltranspeptidase activity and relation to multiple drug therapy.

Authors:  G Heinemeyer; I Roots; P Lestau; H R Klaiber; R Dennhardt
Journal:  Br J Clin Pharmacol       Date:  1986-01       Impact factor: 4.335

8.  Antipyrine metabolite formation and excretion in patients with chronic renal failure.

Authors:  M W Teunissen; D Kampf; I Roots; N P Vermeulen; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

9.  Comparison of single dose kinetics of imipramine, nortriptyline and antipyrine in man.

Authors:  L F Gram; P B Andreasen; K F Overo; J Christiansen
Journal:  Psychopharmacology (Berl)       Date:  1976-10-20       Impact factor: 4.530

10.  Dietary influences on the kinetics of antipyrine and aminopyrine in human subjects.

Authors:  K Krishnaswamy; R Kalamegham; N A Naidu
Journal:  Br J Clin Pharmacol       Date:  1984-02       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.